A large Swedish study of patients undergoing coronary procedures shows that renal failure is more likely to develop with the use of an iso-osmolar rather than low-osmolar contrast media.
Contrast volume:eGFR ratio may be useful in calculating the maximum amount of contrast to give.
Use of ACE inhibitors and angiotensin receptor blockers during coronary angiography found to independently boost risk by 43%.
PRAGUE—Transient hyponatremia may precede development of contrast-induced nephropathy (CIN) in patients undergoing coronary angiography, according to investigators.
LAS VEGAS—Women with an estimated glomerular filtration rate (eGFR) of 60 mL/min/1.73 m2 or higher are at higher risk than men for experiencing radiocontrast-induced nephropathy (RCIN) following coronary angiography, investigators reported at the National Kidney Foundation's Spring Clinical Meetings.
CHICAGO—Brazilian researchers report that acetylcysteine should no longer be used to prevent contrast-induced nephropathy (CIN) in patients undergoing coronary and vascular angiography.
Researchers find no difference between saline and sodium bicarbonate.
Contrast-induced nephropathy (CIN) develops in 11% of emergency department patients who undergo contrast-enhanced CT (CECT).
A recent study shows that sodium bicarbonate is no better than saline in preventing contrast-induced nephropathy (CIN).
Evidence comes from a study comparing two strategies for preventing contrast-induced nephropathy
PLC Medical Systems, Inc., of Franklin, Mass., has received full approval for a U.S. pivotal trial to study the effectiveness of its RenalGuard System and associated therapy in the prevention of contrast-induced nephropathy (CIN).
CHICAGO—Iso-osmolar and low-osmolar contrast agents showed similar nephrotoxicity in a study of patients with impaired renal function undergoing percutaneous coronary intervention (PCI), according to findings presented here at the American College of Cardiology annual meeting.
CHICAGO—Routine use of contrast agents for evaluating chest pain carries a risk of contrast- induced nephropathy (CIN).
WASHINGTON, D.C.—Targeted renal therapy (TRT) involving intrarenal administration of fenoldopam is safe and feasible in patients undergoing angiographic procedures, even in patients at elevated risk of suffering from contrast-induced nephropathy (CIN).
A recent meta-analysis supports administration of N-acetylcysteine prophylaxis to prevent contrast-induced nephropathy, especially in high-risk patients. Researchers also noted that the drug is inexpensive and readily available, and has few side effects.
PLC Systems Inc., of Franklin, Mass., has received conditional approval to begin enrollment in a pivotal trial to study the effectiveness of its RenalGuard Therapy and RenalGuard System in the prevention of contrast-induced nephropathy (CIN).